Insider Selling: Omeros (NASDAQ:OMER) CAO Sells $84,750.00 in Stock

Omeros Corporation (NASDAQ:OMER) CAO David Borges sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $16.95, for a total value of $84,750.00. Following the completion of the sale, the chief accounting officer directly owned 5,000 shares in the company, valued at approximately $84,750. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Up 7.0%

Omeros stock opened at $18.39 on Thursday. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $18.89. The company has a market capitalization of $1.33 billion, a P/E ratio of 14.37 and a beta of 2.54. The stock’s 50 day moving average is $11.35 and its 200 day moving average is $11.66.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, equities analysts expect that Omeros Corporation will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. UBS Group AG grew its position in Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the period. Dimensional Fund Advisors LP increased its position in Omeros by 85.2% during the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company’s stock valued at $1,897,000 after acquiring an additional 82,646 shares during the last quarter. Corient Private Wealth LLC lifted its holdings in Omeros by 13.0% in the fourth quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock valued at $11,817,000 after acquiring an additional 79,263 shares during the period. AlphaQuest LLC boosted its position in Omeros by 8,259,600.0% in the fourth quarter. AlphaQuest LLC now owns 82,597 shares of the biopharmaceutical company’s stock worth $1,419,000 after purchasing an additional 82,596 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after purchasing an additional 666,357 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OMER has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings upgraded Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. HC Wainwright reissued a “buy” rating on shares of Omeros in a report on Monday, July 27th. Finally, Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Omeros has an average rating of “Moderate Buy” and a consensus target price of $38.00.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.